Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures:a Double-blind, Randomized, Active-controlled, Parallel-group, Multicenter Clinical Study.

Next Previous
Trial Profile

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures:a Double-blind, Randomized, Active-controlled, Parallel-group, Multicenter Clinical Study.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eslicarbazepine acetate (Primary) ; Carbamazepine
  • Indications Partial epilepsies
  • Focus Registrational; Therapeutic Use
  • Sponsors BIAL - Portela C S.A.

Most Recent Events

  • 06 Dec 2022 Results of post hoc analysis(n=288) assessing efficacy and safety/tolerability of eslicarbazepine acetate (ESL) monotherapy vs. controlled-release carbamazepine (CBZ-CR) in PTE vs. non-PTE patients presented at the 76th Annual Meeting of the American Epilepsy Society
  • 22 Apr 2021 Results assessing 10 years of post-marketing surveillance (PMS) safety data of eslicarbazepine acetate collected from randomised clinical trials in adults: BIA-2093-201, -301, -302 -303, -304 and -311, presented at the 73rd Annual Meeting of the American Academy of Neurology.
  • 22 Apr 2021 Results of post hoc analysis from NCT02484001 and NCT01162460; evaluating the lipid changes in adult patients with newly diagnosed focal-onset seizures, presented at the 73rd Annual Meeting of the American Academy of Neurology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top